{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+CC-486", "query": { "intervention": "Oral CC-486" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 35, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Oral+CC-486&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-13T09:49:59.969Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02281084", "title": "Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Oral Azacitidine", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2015-07-06", "completion_date": "2023-09-14", "has_results": true, "last_update_posted_date": "2024-10-04", "last_synced_at": "2026-09-13T09:49:59.969Z", "location_count": 23, "location_summary": "New Haven, Connecticut • Miami, Florida • Tampa, Florida + 11 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02281084" }, { "nct_id": "NCT05162976", "title": "CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Classic Hodgkin Lymphoma", "Refractory Classic Hodgkin Lymphoma" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Oral Azacitidine", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2022-01-03", "completion_date": "2027-04-27", "has_results": false, "last_update_posted_date": "2026-06-03", "last_synced_at": "2026-09-13T09:49:59.969Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05162976" }, { "nct_id": "NCT04447027", "title": "Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cutaneous T-Cell Lymphoma", "Mature T-cell Malignancies", "Peripheral T-Cell Lymphoma", "Relapsed/ Refractory T-cell Malignancies" ], "interventions": [ { "name": "Romidepsin", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "CC-486 (5-azacitidine)", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone Marrow Aspiration/Biopsy", "type": "PROCEDURE" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "TTE", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2020-12-17", "completion_date": "2025-12-17", "has_results": true, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-09-13T09:49:59.969Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04447027" }, { "nct_id": "NCT01566695", "title": "The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myelodysplastic Syndrome" ], "interventions": [ { "name": "Oral Azacitidine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Best Supportiv Care (BSC)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 216, "start_date": "2013-04-26", "completion_date": "2023-12-21", "has_results": true, "last_update_posted_date": "2025-01-07", "last_synced_at": "2026-09-13T09:49:59.969Z", "location_count": 40, "location_summary": "Berkeley, California • Beverly Hills, California • Duarte, California + 31 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Greenbrae", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01566695" }, { "nct_id": "NCT01835587", "title": "Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia, Myeloid, Acute", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "CC-486", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2013-10-25", "completion_date": "2017-05-26", "has_results": true, "last_update_posted_date": "2018-11-20", "last_synced_at": "2026-09-13T09:49:59.969Z", "location_count": 4, "location_summary": "New York, New York • Cleveland, Ohio • Houston, Texas + 1 more", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01835587" }, { "nct_id": "NCT04778410", "title": "Study of Magrolimab Combinations in Participants With Myeloid Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloid Malignancies" ], "interventions": [ { "name": "Magrolimab", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Mitoxantrone", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "CC-486", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2021-06-28", "completion_date": "2024-03-04", "has_results": true, "last_update_posted_date": "2025-03-20", "last_synced_at": "2026-09-13T09:49:59.969Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Duarte, California • Los Angeles, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04778410" }, { "nct_id": "NCT02512172", "title": "A Study of Enhancing Response to MK-3475 in Advanced Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Oral CC-486", "type": "DRUG" }, { "name": "Romidepsin", "type": "DRUG" }, { "name": "MK-3475", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2016-02-19", "completion_date": "2021-11-20", "has_results": false, "last_update_posted_date": "2025-12-03", "last_synced_at": "2026-09-13T09:49:59.969Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02512172" }, { "nct_id": "NCT02223052", "title": "Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematological Neoplasms", "Non-Hodgkin's Lymphoma", "Hodgkin's Lymphoma", "Lymphoma", "Multiple Myeloma", "Acute Myeloid Leukemia", "Leukemia", "Myelodysplastic Syndromes", "Neoplasms", "Melanoma", "Breast Cancer", "Metastatic Breast Cancer", "Non-Small Cell Lung Cancer", "Small Cell Lung Cancer", "Renal Cell Carcinoma", "Glioblastoma Multiforme", "Osteosarcoma", "Sarcoma", "Thyroid Cancer", "Genitourinary" ], "interventions": [ { "name": "CC-486", "type": "DRUG" }, { "name": "Vidaza", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2014-10-27", "completion_date": "2018-12-18", "has_results": false, "last_update_posted_date": "2020-05-12", "last_synced_at": "2026-09-13T09:49:59.969Z", "location_count": 10, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Iowa City, Iowa + 6 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02223052" }, { "nct_id": "NCT04803201", "title": "Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Angioimmunoblastic T-cell Lymphoma", "Enteropathy-Associated T-Cell Lymphoma", "Follicular T-Cell Lymphoma", "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma", "Nodal Peripheral T-Cell Lymphoma With TFH Phenotype", "Peripheral T-Cell Lymphoma, Not Otherwise Specified" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Duvelisib", "type": "DRUG" }, { "name": "Oral azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 170, "start_date": "2021-10-08", "completion_date": "2027-05-19", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-13T09:49:59.969Z", "location_count": 96, "location_summary": "Little Rock, Arkansas • Duarte, California • La Jolla, California + 74 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04803201" }, { "nct_id": "NCT00528983", "title": "Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelodysplastic Syndromes (MDS)", "Chronic Myelomonocytic Leukemia (CMML)", "Acute Myelogenous Leukemia (AML)" ], "interventions": [ { "name": "Subcutaneous (SC) Azacitidine", "type": "DRUG" }, { "name": "Oral Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 133, "start_date": "2007-09-11", "completion_date": "2016-04-05", "has_results": false, "last_update_posted_date": "2019-11-08", "last_synced_at": "2026-09-13T09:49:59.969Z", "location_count": 18, "location_summary": "Gainesville, Florida • Chicago, Illinois • Indianapolis, Indiana + 15 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00528983" } ] }